PROSpECT-PRIOR-2-CHEMO: PRIOR Dental Intervention Before Chemo to Reduce Chemotherapy Complications
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Leeds
About this trial
The aim of this feasibility trial is to determine if it is safe and feasible to treat oral health diseases in people with haematological cancers before they start their chemotherapy to reduce complications and disruption to planned chemotherapy dose or schedule.
Eligibility criteria
Qualifiers
Myeloma- Autologous Stem Cell Transplantation (ASCT) before high-dose myeloablative CT.
Haematological cancers suitable for Allografts Stem Cell Transplant (SCT) before CT
Clinical evidence of caries (2+ teeth)
Clinical evidence on soft and hard tissue examination of infection, sinus, swelling or tenderness
Disqualifiers
Have a history of head and neck radiotherapy
Have been treated with Denusomab, Bevacizumab, Sunitinib or Aflibercept within 9 months of the MDT date.
Insufficient teeth [defined as <2]
Are incapable of providing informed written consent
Trial design
Treatments tested in this trial
- PRIOR [Proactive Intensive Oral Review & Treatment]
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of Leeds
Lead sponsor
The Leeds Teaching Hospitals NHS Trust
Collaborator
Source ClinicalTrials.gov